Author Correction: The current landscape of nucleic acid therapeutics (Nature Nanotechnology, (2021), 16, 6, (630-643), 10.1038/s41565-021-00898-0)

Jayesh A. Kulkarni; Dominik Witzigmann; Sarah B. Thomson; Sam Chen; Blair R. Leavitt; Pieter R. Cullis; Roy van der Meel

doi:10.1038/s41565-021-00937-w

Author Correction: The current landscape of nucleic acid therapeutics (Nature Nanotechnology, (2021), 16, 6, (630-643), 10.1038/s41565-021-00898-0)

Jayesh A. Kulkarni, Dominik Witzigmann, Sarah B. Thomson, Sam Chen, Blair R. Leavitt, Pieter R. Cullis, Roy van der Meel (Corresponding author)

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

11 Citations (Scopus)

59 Downloads (Pure)

Abstract

In Table 2 of the version of this Review originally published, the nucleic acid therapeutic ‘Nedosiran’ was incorrectly listed as a GalNAc– ASO conjugate, but it is a GalNAc–siRNA conjugate. Table 2 has now been amended accordingly in the online versions of the Review.

Original language	English
Pages (from-to)	841
Number of pages	1
Journal	Nature Nanotechnology
Volume	16
Issue number	7
DOIs	https://doi.org/10.1038/s41565-021-00937-w
Publication status	Published - Jul 2021

Access to Document

10.1038/s41565-021-00937-w

s41565-021-00937-wFinal published version, 574 KB

Cite this

@article{215784b13327427dbe20e8a3021cafd8,

title = "Author Correction: The current landscape of nucleic acid therapeutics (Nature Nanotechnology, (2021), 16, 6, (630-643), 10.1038/s41565-021-00898-0)",

abstract = "In Table 2 of the version of this Review originally published, the nucleic acid therapeutic {\textquoteleft}Nedosiran{\textquoteright} was incorrectly listed as a GalNAc– ASO conjugate, but it is a GalNAc–siRNA conjugate. Table 2 has now been amended accordingly in the online versions of the Review.",

author = "Kulkarni, {Jayesh A.} and Dominik Witzigmann and Thomson, {Sarah B.} and Sam Chen and Leavitt, {Blair R.} and Cullis, {Pieter R.} and {van der Meel}, Roy",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2021",

month = jul,

doi = "10.1038/s41565-021-00937-w",

language = "English",

volume = "16",

pages = "841",

journal = "Nature Nanotechnology",

issn = "1748-3387",

publisher = "Nature Publishing Group",

number = "7",

}

Author Correction: The current landscape of nucleic acid therapeutics (Nature Nanotechnology, (2021), 16, 6, (630-643), 10.1038/s41565-021-00898-0). / Kulkarni, Jayesh A.; Witzigmann, Dominik; Thomson, Sarah B. et al.
In: Nature Nanotechnology, Vol. 16, No. 7, 07.2021, p. 841.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Author Correction

T2 - The current landscape of nucleic acid therapeutics (Nature Nanotechnology, (2021), 16, 6, (630-643), 10.1038/s41565-021-00898-0)

AU - Kulkarni, Jayesh A.

AU - Witzigmann, Dominik

AU - Thomson, Sarah B.

AU - Chen, Sam

AU - Leavitt, Blair R.

AU - Cullis, Pieter R.

AU - van der Meel, Roy

PY - 2021/7

Y1 - 2021/7

N2 - In Table 2 of the version of this Review originally published, the nucleic acid therapeutic ‘Nedosiran’ was incorrectly listed as a GalNAc– ASO conjugate, but it is a GalNAc–siRNA conjugate. Table 2 has now been amended accordingly in the online versions of the Review.

AB - In Table 2 of the version of this Review originally published, the nucleic acid therapeutic ‘Nedosiran’ was incorrectly listed as a GalNAc– ASO conjugate, but it is a GalNAc–siRNA conjugate. Table 2 has now been amended accordingly in the online versions of the Review.

UR - http://www.scopus.com/inward/record.url?scp=85112121494&partnerID=8YFLogxK

U2 - 10.1038/s41565-021-00937-w

DO - 10.1038/s41565-021-00937-w

M3 - Comment/Letter to the editor

C2 - 34194013

AN - SCOPUS:85112121494

SN - 1748-3387

VL - 16

SP - 841

JO - Nature Nanotechnology

JF - Nature Nanotechnology

IS - 7

ER -

Author Correction: The current landscape of nucleic acid therapeutics (Nature Nanotechnology, (2021), 16, 6, (630-643), 10.1038/s41565-021-00898-0)

Abstract

Access to Document

Other files and links

Fingerprint

The current landscape of nucleic acid therapeutics

Cite this